Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.
Identifieur interne : 000E38 ( PubMed/Curation ); précédent : 000E37; suivant : 000E39Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.
Auteurs : Mairéad Geraldine Mcnamara [Royaume-Uni] ; John Bridgewater [Royaume-Uni] ; Andre Lopes [Royaume-Uni] ; Harpreet Wasan [Royaume-Uni] ; David Malka [France] ; Lars Henrik Jensen [Danemark] ; Takuji Okusaka [Japon] ; Jennifer J. Knox [Canada] ; Dorothea Wagner [Suisse] ; David Cunningham [Royaume-Uni] ; Jenny Shannon [Australie] ; David Goldstein [Australie] ; Markus Moehler [Allemagne] ; Tanios Bekaii-Saab [États-Unis] ; Juan W. Valle [Royaume-Uni]Source :
- BMC cancer [ 1471-2407 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Analyse de survie, Carboplatine (administration et posologie), Carboplatine (usage thérapeutique), Cisplatine (administration et posologie), Cisplatine (usage thérapeutique), Femelle, Humains, Jeune adulte, Mâle, Protocoles de polychimiothérapie antinéoplasique (administration et posologie), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Tumeurs des voies biliaires (anatomopathologie), Tumeurs des voies biliaires (traitement médicamenteux), Études prospectives.
- MESH :
- administration et posologie : Carboplatine, Cisplatine, Protocoles de polychimiothérapie antinéoplasique.
- anatomopathologie : Tumeurs des voies biliaires.
- traitement médicamenteux : Tumeurs des voies biliaires.
- usage thérapeutique : Carboplatine, Cisplatine, Protocoles de polychimiothérapie antinéoplasique.
- Adulte, Adulte d'âge moyen, Analyse de survie, Femelle, Humains, Jeune adulte, Mâle, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Études prospectives.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Biliary Tract Neoplasms (drug therapy), Biliary Tract Neoplasms (pathology), Carboplatin (administration & dosage), Carboplatin (therapeutic use), Cisplatin (administration & dosage), Cisplatin (therapeutic use), Disease-Free Survival, Female, Humans, Male, Middle Aged, Prospective Studies, Survival Analysis, Treatment Outcome, Young Adult.
- MESH :
- chemical , administration & dosage : Carboplatin, Cisplatin.
- administration & dosage : Antineoplastic Combined Chemotherapy Protocols.
- drug therapy : Biliary Tract Neoplasms.
- pathology : Biliary Tract Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Cisplatin.
- Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Humans, Male, Middle Aged, Prospective Studies, Survival Analysis, Treatment Outcome, Young Adult.
Abstract
Outcomes in younger (<40 years) and elderly (≥70 years) patients with advanced biliary cancer (ABC) receiving palliative chemotherapy are unclear. This study assessed outcomes in those receiving monotherapy or combination therapy in thirteen prospective systemic-therapy trials.
DOI: 10.1186/s12885-017-3266-9
PubMed: 28403829
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000E41
Links to Exploration step
pubmed:28403829Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.</title><author><name sortKey="Mcnamara, Mairead Geraldine" sort="Mcnamara, Mairead Geraldine" uniqKey="Mcnamara M" first="Mairéad Geraldine" last="Mcnamara">Mairéad Geraldine Mcnamara</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular & Clinical Cancer Sciences, Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, M20 4BX, UK. Mairead.McNamara@christie.nhs.uk.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Molecular & Clinical Cancer Sciences, Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, M20 4BX</wicri:regionArea></affiliation></author><author><name sortKey="Bridgewater, John" sort="Bridgewater, John" uniqKey="Bridgewater J" first="John" last="Bridgewater">John Bridgewater</name><affiliation wicri:level="1"><nlm:affiliation>UCL Cancer Institute, London, WCIE 6BT, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>UCL Cancer Institute, London, WCIE 6BT</wicri:regionArea></affiliation></author><author><name sortKey="Lopes, Andre" sort="Lopes, Andre" uniqKey="Lopes A" first="Andre" last="Lopes">Andre Lopes</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research UK & UCL Cancer Trials Centre, London, WCIE 6BT, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cancer Research UK & UCL Cancer Trials Centre, London, WCIE 6BT</wicri:regionArea></affiliation></author><author><name sortKey="Wasan, Harpreet" sort="Wasan, Harpreet" uniqKey="Wasan H" first="Harpreet" last="Wasan">Harpreet Wasan</name><affiliation wicri:level="1"><nlm:affiliation>Imperial Healthcare, London, WI2 ONN, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Imperial Healthcare, London, WI2 ONN</wicri:regionArea></affiliation></author><author><name sortKey="Malka, David" sort="Malka, David" uniqKey="Malka D" first="David" last="Malka">David Malka</name><affiliation wicri:level="1"><nlm:affiliation>Institute Gustave Roussy, 94805, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institute Gustave Roussy, 94805, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Jensen, Lars Henrik" sort="Jensen, Lars Henrik" uniqKey="Jensen L" first="Lars Henrik" last="Jensen">Lars Henrik Jensen</name><affiliation wicri:level="1"><nlm:affiliation>Vejle Hospital, 7100, Vejle, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Vejle Hospital, 7100, Vejle</wicri:regionArea></affiliation></author><author><name sortKey="Okusaka, Takuji" sort="Okusaka, Takuji" uniqKey="Okusaka T" first="Takuji" last="Okusaka">Takuji Okusaka</name><affiliation wicri:level="1"><nlm:affiliation>National Cancer Center Hospital, Tokyo, 104-0045, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>National Cancer Center Hospital, Tokyo, 104-0045</wicri:regionArea></affiliation></author><author><name sortKey="Knox, Jennifer J" sort="Knox, Jennifer J" uniqKey="Knox J" first="Jennifer J" last="Knox">Jennifer J. Knox</name><affiliation wicri:level="1"><nlm:affiliation>Princess Margaret Cancer Centre, Toronto, M5G 2M9, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Princess Margaret Cancer Centre, Toronto, M5G 2M9</wicri:regionArea></affiliation></author><author><name sortKey="Wagner, Dorothea" sort="Wagner, Dorothea" uniqKey="Wagner D" first="Dorothea" last="Wagner">Dorothea Wagner</name><affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier Universitaire Vaudois, CH-1011, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Centre Hospitalier Universitaire Vaudois, CH-1011, Lausanne</wicri:regionArea></affiliation></author><author><name sortKey="Cunningham, David" sort="Cunningham, David" uniqKey="Cunningham D" first="David" last="Cunningham">David Cunningham</name><affiliation wicri:level="1"><nlm:affiliation>Royal Marsden Hospital, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea></affiliation></author><author><name sortKey="Shannon, Jenny" sort="Shannon, Jenny" uniqKey="Shannon J" first="Jenny" last="Shannon">Jenny Shannon</name><affiliation wicri:level="1"><nlm:affiliation>University of Sydney, Sydney, NSW, 2006, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>University of Sydney, Sydney, NSW, 2006</wicri:regionArea></affiliation></author><author><name sortKey="Goldstein, David" sort="Goldstein, David" uniqKey="Goldstein D" first="David" last="Goldstein">David Goldstein</name><affiliation wicri:level="1"><nlm:affiliation>Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, 2052</wicri:regionArea></affiliation></author><author><name sortKey="Moehler, Markus" sort="Moehler, Markus" uniqKey="Moehler M" first="Markus" last="Moehler">Markus Moehler</name><affiliation wicri:level="1"><nlm:affiliation>Universitätsmedizin Mainz, 55122, Mainz, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Universitätsmedizin Mainz, 55122, Mainz</wicri:regionArea></affiliation></author><author><name sortKey="Bekaii Saab, Tanios" sort="Bekaii Saab, Tanios" uniqKey="Bekaii Saab T" first="Tanios" last="Bekaii-Saab">Tanios Bekaii-Saab</name><affiliation wicri:level="1"><nlm:affiliation>Mayo Clinic, Phoenix, AZ, 85054, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mayo Clinic, Phoenix, AZ, 85054</wicri:regionArea></affiliation></author><author><name sortKey="Valle, Juan W" sort="Valle, Juan W" uniqKey="Valle J" first="Juan W" last="Valle">Juan W. Valle</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular & Clinical Cancer Sciences, Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, M20 4BX, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Molecular & Clinical Cancer Sciences, Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, M20 4BX</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28403829</idno><idno type="pmid">28403829</idno><idno type="doi">10.1186/s12885-017-3266-9</idno><idno type="wicri:Area/PubMed/Corpus">000E41</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E41</idno><idno type="wicri:Area/PubMed/Curation">000E38</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E38</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.</title><author><name sortKey="Mcnamara, Mairead Geraldine" sort="Mcnamara, Mairead Geraldine" uniqKey="Mcnamara M" first="Mairéad Geraldine" last="Mcnamara">Mairéad Geraldine Mcnamara</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular & Clinical Cancer Sciences, Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, M20 4BX, UK. Mairead.McNamara@christie.nhs.uk.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Molecular & Clinical Cancer Sciences, Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, M20 4BX</wicri:regionArea></affiliation></author><author><name sortKey="Bridgewater, John" sort="Bridgewater, John" uniqKey="Bridgewater J" first="John" last="Bridgewater">John Bridgewater</name><affiliation wicri:level="1"><nlm:affiliation>UCL Cancer Institute, London, WCIE 6BT, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>UCL Cancer Institute, London, WCIE 6BT</wicri:regionArea></affiliation></author><author><name sortKey="Lopes, Andre" sort="Lopes, Andre" uniqKey="Lopes A" first="Andre" last="Lopes">Andre Lopes</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research UK & UCL Cancer Trials Centre, London, WCIE 6BT, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cancer Research UK & UCL Cancer Trials Centre, London, WCIE 6BT</wicri:regionArea></affiliation></author><author><name sortKey="Wasan, Harpreet" sort="Wasan, Harpreet" uniqKey="Wasan H" first="Harpreet" last="Wasan">Harpreet Wasan</name><affiliation wicri:level="1"><nlm:affiliation>Imperial Healthcare, London, WI2 ONN, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Imperial Healthcare, London, WI2 ONN</wicri:regionArea></affiliation></author><author><name sortKey="Malka, David" sort="Malka, David" uniqKey="Malka D" first="David" last="Malka">David Malka</name><affiliation wicri:level="1"><nlm:affiliation>Institute Gustave Roussy, 94805, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institute Gustave Roussy, 94805, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Jensen, Lars Henrik" sort="Jensen, Lars Henrik" uniqKey="Jensen L" first="Lars Henrik" last="Jensen">Lars Henrik Jensen</name><affiliation wicri:level="1"><nlm:affiliation>Vejle Hospital, 7100, Vejle, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Vejle Hospital, 7100, Vejle</wicri:regionArea></affiliation></author><author><name sortKey="Okusaka, Takuji" sort="Okusaka, Takuji" uniqKey="Okusaka T" first="Takuji" last="Okusaka">Takuji Okusaka</name><affiliation wicri:level="1"><nlm:affiliation>National Cancer Center Hospital, Tokyo, 104-0045, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>National Cancer Center Hospital, Tokyo, 104-0045</wicri:regionArea></affiliation></author><author><name sortKey="Knox, Jennifer J" sort="Knox, Jennifer J" uniqKey="Knox J" first="Jennifer J" last="Knox">Jennifer J. Knox</name><affiliation wicri:level="1"><nlm:affiliation>Princess Margaret Cancer Centre, Toronto, M5G 2M9, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Princess Margaret Cancer Centre, Toronto, M5G 2M9</wicri:regionArea></affiliation></author><author><name sortKey="Wagner, Dorothea" sort="Wagner, Dorothea" uniqKey="Wagner D" first="Dorothea" last="Wagner">Dorothea Wagner</name><affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier Universitaire Vaudois, CH-1011, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Centre Hospitalier Universitaire Vaudois, CH-1011, Lausanne</wicri:regionArea></affiliation></author><author><name sortKey="Cunningham, David" sort="Cunningham, David" uniqKey="Cunningham D" first="David" last="Cunningham">David Cunningham</name><affiliation wicri:level="1"><nlm:affiliation>Royal Marsden Hospital, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea></affiliation></author><author><name sortKey="Shannon, Jenny" sort="Shannon, Jenny" uniqKey="Shannon J" first="Jenny" last="Shannon">Jenny Shannon</name><affiliation wicri:level="1"><nlm:affiliation>University of Sydney, Sydney, NSW, 2006, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>University of Sydney, Sydney, NSW, 2006</wicri:regionArea></affiliation></author><author><name sortKey="Goldstein, David" sort="Goldstein, David" uniqKey="Goldstein D" first="David" last="Goldstein">David Goldstein</name><affiliation wicri:level="1"><nlm:affiliation>Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, 2052</wicri:regionArea></affiliation></author><author><name sortKey="Moehler, Markus" sort="Moehler, Markus" uniqKey="Moehler M" first="Markus" last="Moehler">Markus Moehler</name><affiliation wicri:level="1"><nlm:affiliation>Universitätsmedizin Mainz, 55122, Mainz, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Universitätsmedizin Mainz, 55122, Mainz</wicri:regionArea></affiliation></author><author><name sortKey="Bekaii Saab, Tanios" sort="Bekaii Saab, Tanios" uniqKey="Bekaii Saab T" first="Tanios" last="Bekaii-Saab">Tanios Bekaii-Saab</name><affiliation wicri:level="1"><nlm:affiliation>Mayo Clinic, Phoenix, AZ, 85054, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mayo Clinic, Phoenix, AZ, 85054</wicri:regionArea></affiliation></author><author><name sortKey="Valle, Juan W" sort="Valle, Juan W" uniqKey="Valle J" first="Juan W" last="Valle">Juan W. Valle</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular & Clinical Cancer Sciences, Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, M20 4BX, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Molecular & Clinical Cancer Sciences, Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, M20 4BX</wicri:regionArea></affiliation></author></analytic><series><title level="j">BMC cancer</title><idno type="eISSN">1471-2407</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Combined Chemotherapy Protocols (administration & dosage)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Biliary Tract Neoplasms (drug therapy)</term><term>Biliary Tract Neoplasms (pathology)</term><term>Carboplatin (administration & dosage)</term><term>Carboplatin (therapeutic use)</term><term>Cisplatin (administration & dosage)</term><term>Cisplatin (therapeutic use)</term><term>Disease-Free Survival</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Survival Analysis</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de survie</term><term>Carboplatine (administration et posologie)</term><term>Carboplatine (usage thérapeutique)</term><term>Cisplatine (administration et posologie)</term><term>Cisplatine (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Protocoles de polychimiothérapie antinéoplasique (administration et posologie)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Tumeurs des voies biliaires (anatomopathologie)</term><term>Tumeurs des voies biliaires (traitement médicamenteux)</term><term>Études prospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Carboplatin</term><term>Cisplatin</term></keywords><keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Carboplatine</term><term>Cisplatine</term><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs des voies biliaires</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Biliary Tract Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Biliary Tract Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Carboplatin</term><term>Cisplatin</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs des voies biliaires</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Carboplatine</term><term>Cisplatine</term><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Disease-Free Survival</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Survival Analysis</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de survie</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Études prospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Outcomes in younger (<40 years) and elderly (≥70 years) patients with advanced biliary cancer (ABC) receiving palliative chemotherapy are unclear. This study assessed outcomes in those receiving monotherapy or combination therapy in thirteen prospective systemic-therapy trials.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28403829</PMID><DateCreated><Year>2017</Year><Month>04</Month><Day>13</Day></DateCreated><DateCompleted><Year>2017</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2017</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2407</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Apr</Month><Day>12</Day></PubDate></JournalIssue><Title>BMC cancer</Title><ISOAbbreviation>BMC Cancer</ISOAbbreviation></Journal><ArticleTitle>Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.</ArticleTitle><Pagination><MedlinePgn>262</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-017-3266-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Outcomes in younger (<40 years) and elderly (≥70 years) patients with advanced biliary cancer (ABC) receiving palliative chemotherapy are unclear. This study assessed outcomes in those receiving monotherapy or combination therapy in thirteen prospective systemic-therapy trials.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Multivariable analysis explored the impact of therapy on progression-free (PFS) and overall survival (OS) in two separate age cohort groups: <70 years and ≥70 years, and <40 years and ≥40 years.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 1163 patients were recruited (Jan 1997-Dec 2013). Median age of entire cohort: 63 years (range 23-85); 36 (3%) were <40, 260 (22%); ≥70. Combination therapy was platinum-based in nine studies. Among patients <40 and ≥70 years, 23 (64%) and 182 (70%) received combination therapy, respectively. Median follow-up was 42 months (95%-CI 37-51). Median PFS for patients <40 and ≥40 years was 3.5 and 5.9 months (P = 0.12), and OS was 10.8 and 9.7 months, respectively (P = 0.55). Median PFS for those <70 and ≥70 years was 6.0 and 5.0 months (P = 0.53), and OS was 10.2 and 8.8 months, respectively (P = 0.08). For the entire cohort, PFS and OS were significantly better in those receiving combination therapy: Hazard Ratio [HR]-0.66, 95%-CI 0.58-0.76, P < 0.0001 and HR-0.72, 95%-CI 0.63-0.82, P < 0.0001, respectively; and in patients ≥70 years: HR-0.54 (95%-CI 0.38-0.77, P = 0.001) and HR-0.60 (95%-CI 0.43-0.85, P = 0.004), respectively. There was no evidence of interaction between age and treatment for PFS (P = 0.58, P = 0.66) or OS (P = 0.18, P = 0.75).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In ABC, younger patients are rare, and survival in elderly patients in receipt of systemic therapy for advanced disease, whether monotherapy or combination therapy, is similar to that of non-elderly patients, therefore age alone should not influence decisions regarding treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McNamara</LastName><ForeName>Mairéad Geraldine</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Division of Molecular & Clinical Cancer Sciences, Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, M20 4BX, UK. Mairead.McNamara@christie.nhs.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bridgewater</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>UCL Cancer Institute, London, WCIE 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>Andre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cancer Research UK & UCL Cancer Trials Centre, London, WCIE 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wasan</LastName><ForeName>Harpreet</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Imperial Healthcare, London, WI2 ONN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malka</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute Gustave Roussy, 94805, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Lars Henrik</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Vejle Hospital, 7100, Vejle, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okusaka</LastName><ForeName>Takuji</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>National Cancer Center Hospital, Tokyo, 104-0045, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knox</LastName><ForeName>Jennifer J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Princess Margaret Cancer Centre, Toronto, M5G 2M9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Dorothea</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire Vaudois, CH-1011, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Royal Marsden Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shannon</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Sydney, Sydney, NSW, 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moehler</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universitätsmedizin Mainz, 55122, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bekaii-Saab</LastName><ForeName>Tanios</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Phoenix, AZ, 85054, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valle</LastName><ForeName>Juan W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Division of Molecular & Clinical Cancer Sciences, Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, M20 4BX, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Cancer</MedlineTA><NlmUniqueID>100967800</NlmUniqueID><ISSNLinking>1471-2407</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>BG3F62OND5</RegistryNumber><NameOfSubstance UI="D016190">Carboplatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q20Q21Q62J</RegistryNumber><NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Apr 8;362(14):1273-81</RefSource><PMID Version="1">20375404</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Sep 1;29(25):3457-65</RefSource><PMID Version="1">21810685</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2015 Nov 10;33(32):3826-33</RefSource><PMID Version="1">26195697</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2014 Dec;50(18):3125-35</RefSource><PMID Version="1">25446376</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2014 Feb;25(2):391-8</RefSource><PMID Version="1">24351397</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Jun 10;29(17 ):2357-63</RefSource><PMID Version="1">21519026</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Chemother Pharmacol. 2016 Aug;78(2):361-7</RefSource><PMID Version="1">27335026</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Crit Rev Oncol Hematol. 2011 Oct;80(1):31-9</RefSource><PMID Version="1">21094052</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2010 Aug 10;103(4):469-74</RefSource><PMID Version="1">20628385</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer J. 2005 Nov-Dec;11(6):461-73</RefSource><PMID Version="1">16393480</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncotarget. 2015 Dec 29;6(42):44995-5004</RefSource><PMID Version="1">26575326</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2005 May 9;92(9):1650-4</RefSource><PMID Version="1">15856037</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Cancer. 2015 May 06;15:359</RefSource><PMID Version="1">25943747</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2004 Feb 18;96(4):261-8</RefSource><PMID Version="1">14970275</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Chemother Pharmacol. 2011 Mar;67(3):519-25</RefSource><PMID Version="1">20461378</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2009 Dec 1;101(11):1846-52</RefSource><PMID Version="1">19904267</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Surg. 2004 Apr;187(4):559-63</RefSource><PMID Version="1">15041513</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hepatogastroenterology. 2011 Mar-Apr;58(106):270-4</RefSource><PMID Version="1">21661380</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2016 Apr 26;114(9):965-71</RefSource><PMID Version="1">27115567</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncologist. 2000;5(3):224-37</RefSource><PMID Version="1">10884501</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2014 Jul;15(8):819-28</RefSource><PMID Version="1">24852116</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2013 May;24(5):1306-12</RefSource><PMID Version="1">23293115</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>CA Cancer J Clin. 2013 Jan;63(1):11-30</RefSource><PMID Version="1">23335087</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 May 20;30(15):1813-21</RefSource><PMID Version="1">22529258</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Gastroenterol Hepatol. 2014 Feb;29(2):403-8</RefSource><PMID Version="1">23869919</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2007 May 10;25(14):1824-31</RefSource><PMID Version="1">17488980</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2012 Sep;23 (9):2341-6</RefSource><PMID Version="1">22367707</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2016 Jul 10;34(20):2366-71</RefSource><PMID Version="1">27185838</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Crit Rev Oncol Hematol. 2011 Sep;79(3):302-7</RefSource><PMID Version="1">20888781</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer J. 2005 Nov-Dec;11(6):449-60</RefSource><PMID Version="1">16393479</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2016 Jan;27(1):134-40</RefSource><PMID Version="1">26483051</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Oncol. 2011 Apr;50(3):448-54</RefSource><PMID Version="1">20670085</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2007 Sep 15;110(6):1307-12</RefSource><PMID Version="1">17628484</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncology. 2012;82(3):175-9</RefSource><PMID Version="1">22433475</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>World J Surg Oncol. 2015 Feb 12;13:38</RefSource><PMID Version="1">25889848</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2012 Jul 1;118(13):3377-86</RefSource><PMID Version="1">22072065</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Oct;14(11):1077-85</RefSource><PMID Version="1">24028813</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001661" MajorTopicYN="N">Biliary Tract Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016190" MajorTopicYN="N">Carboplatin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biliary cancer</Keyword><Keyword MajorTopicYN="N">Elderly</Keyword><Keyword MajorTopicYN="N">Prospective trials</Keyword><Keyword MajorTopicYN="N">Systemic therapy</Keyword><Keyword MajorTopicYN="N">Younger patients</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>04</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28403829</ArticleId><ArticleId IdType="doi">10.1186/s12885-017-3266-9</ArticleId><ArticleId IdType="pii">10.1186/s12885-017-3266-9</ArticleId><ArticleId IdType="pmc">PMC5389161</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E38 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000E38 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:28403829
|texte= Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:28403829" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |